Probiotix Health reports revenue growth and robust margins for 2024

Published 29/05/2025, 07:18
Probiotix Health reports revenue growth and robust margins for 2024

LONDON - Probiotix Health Plc (AQSE:PBX), a company specializing in the development of probiotics for cardiometabolic health, has reported a positive financial outcome for the year ending December 31, 2024. The company announced a 13% increase in sales, reaching £1.883 million compared to £1.673 million the previous year. This growth has also translated into a 14% rise in gross profit, which amounted to £997,000, with a steady gross profit margin of 53%.

The financial position of Probiotix Health remains solid, with cash balances totaling £1.65 million, showing an improvement from £1.50 million in 2023. The company has credited its financial success to the onboarding of a record number of new customers and distributors, as well as a robust order book indicating strong current trading.

Following the close of the period, Probiotix Health has signed a significant new supply agreement with Kemin China Technology in the Far East and secured a long-term business relationship with TopHealth in South Korea. Additionally, the company has expanded its product portfolio with the launch of YourBiotixMH & PMH, new menopause and post-menopause formulations aimed at women’s health.

The CEO of Probiotix Health, Steen Andersen, expressed confidence in the company’s trajectory, citing a record order book for the current year, significantly ahead of 2024. With new product launches planned in North America and Europe, the company is optimistic about its progress toward reaching break-even in 2025. Andersen also highlighted the company’s strategic focus on expanding commercial efforts within Europe and exploring key potential new markets.

Probiotix Health is hosting an investor presentation today to discuss these results and provide further insights into their strategy and outlook. This event is part of the company’s ongoing engagement with both existing and potential shareholders.

The information in this article is based on a press release statement from Probiotix Health Plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.